Medication info
Trajenta Duo Tablet 2.5/500 mg

Trajenta Duo Tablet 2.5/500 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Boehringer Ingelheim Korea
Appearance
Biconvex oval film-coated tablets of bright yellow color
Packaging
60 tablets/box [(10 tablets/PTP packaging x 6 pieces)]
Approval status
Active

MFDS item code 201208290 · Approved 2012.11.15 · Insurance code 653501390

Summary

Main use
Improvement of blood glucose control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased up to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take the same doses of linagliptin and metformin as they were previously taking as the initial dose. 3. Patients not achieving adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may result in changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use 2. Patients in Whom This Medicine Must Not Be Used).

Ingredients

Importer
Boehringer Ingelheim Korea

Efficacy & effects

Improvement of blood glucose control in patients with type 2 diabetes

View approved original text

This medication is prescribed to assist in blood sugar control for patients with type 2 diabetes using both linagliptin and metformin together. It helps to enhance the efficacy of blood sugar management when combined with diet and exercise. Therefore, this medication is used to improve blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased up to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take the same doses of linagliptin and metformin as they were previously taking as the initial dose. 3. Patients not achieving adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may result in changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use 2. Patients in Whom This Medicine Must Not Be Used).

Precautions

This medication is used for the treatment of diabetes and acts by combining two components to help control blood sugar levels. Care should be taken when taking this medication due to the rare side effect known as lactic acidosis. Lactic acidosis can lead to a serious condition where lactic acid builds up excessively in the body, so if symptoms such as sudden abdominal pain, muscle cramps, weakness, or difficulty breathing occur, consult a doctor immediately. Patients with poor kidney function or liver dysfunction and those with serious diseases of the heart or lungs should avoid taking this medication for safety. It is recommended that women who are pregnant or may become pregnant, as well as nursing mothers, do not use this medication. The risk of hypoglycemia may increase when this medication is used in conjunction with other blood glucose-lowering agents, so blood glucose levels should be monitored frequently, and the doctor may adjust the dose as needed. In addition, since this medication is excreted through the kidneys, regular kidney function tests should be conducted, and if kidney function declines, discontinuation may be necessary. When iodinated contrast media is administered for radiologic examinations, this medication should be temporarily discontinued for a specified period before and after the tests, and it may also need to be stopped for a period before surgery. Rare side effects such as acute pancreatitis or blistering conditions like bullous pemphigoid may occur while taking this medication, so if severe abdominal pain or skin changes occur, it is important to inform a doctor immediately. This medication can lower vitamin B12 levels, so it is advisable to regularly check vitamin B12 concentrations during long-term use. In the elderly, renal function decline is common, so kidney function should be regularly monitored when taking this medication, and caution should be exercised not to exceed the maximum dosage. Possible drug interactions could occur, so if you are currently taking other medications, it is crucial to inform your doctor or pharmacist, especially when taking drugs that may affect kidney function. Finally, this medication has not been established for safety and efficacy in children under 10 years old and is not recommended for use in this age group.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • hypoglycemia
  • taste disturbance
  • cough
  • decreased appetite
Show 135 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • formation of oral ulcers
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • lipase increase
  • amylase increase
  • constipation
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer’s dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • erectile dysfunction
  • goiter
  • anemia
  • headache
  • drowsiness
  • chest discomfort
  • myasthenia
  • epistaxis
  • oropharyngeal pain
  • dysphonia
  • nosebleed
  • androgenic alopecia
  • hyperhidrosis
  • hair loss
  • dermatitis
  • anxiety
  • insomnia
  • depression
  • hypertension
  • benign prostatic hyperplasia
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • anal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • gingivitis
  • increased blood creatinine
  • facial edema
  • hyperthermia
  • back pain
  • osteoarthritis
  • limb pain
  • rotator cuff syndrome
  • dizziness
  • diabetic neuropathy
  • subdural effusion
  • palpitations
  • confusion
  • nocturia
  • pruritus
  • hypercholesterolemia
  • increased blood glucose
  • increased triglycerides in blood
  • decreased hemoglobin
  • increased potassium in blood
  • ALT increase
  • AST increase
  • hearing loss
  • fever
  • pain
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • laceration
  • dry eye
  • cataract
  • eye discomfort
  • allergic conjunctivitis
  • increased blood pressure

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, it should be kept away from excessively hot or cold places, ideally at room temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Biconvex oval film-coated tablets of bright yellow color

Package unit

60 tablets/box [(10 tablets/PTP packaging x 6 pieces)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.